Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 9/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.38 |
| ▸ | FASN | P49327 | 4/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | GALR3 | O60755 | 1/20 | 0.37 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SCD | O00767 | 2/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5312649 | 0.87 | SCD (0.43) | FAAHSCD | |
| SCHEMBL5310015 | 0.85 | SCD (0.51) | FASNSCD | |
| SCHEMBL5312567 | 0.85 | FAAH (0.37) | FAAHKDM4EKCNQ3KCNQ2SCD | |
| SCHEMBL5306277 | 0.84 | FAAH (0.37) | FAAHKDM4ESCDHDAC2 | |
| SCHEMBL5312568 | 0.80 | FAAH (0.37) | FAAHKDM4EHDAC2 | |
| SCHEMBL5309805 | 0.78 | SCD (0.43) | KDM4EKCNQ3KCNQ2FASNPKM | |
| SCHEMBL5311766 | 0.77 | F10 (0.47) | PKMRAB9A | |
| SCHEMBL5309112 | 0.76 | SCD (0.53) | KDM4EFASNRAB9ASCD | |
| SCHEMBL5312271 | 0.74 | KCNQ3 (0.48) | KDM4EKCNQ3KCNQ2FASNPKM | |
| SCHEMBL5306259 | 0.73 | SCD (0.38) | FAAHSCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007046867-A2 | PIPERIDINE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2007-04-26 | — | — | WO | disclosed |